Darby International Exits Pharma Consulting Group S.A. (Biopas)
WASHINGTON, DC, July 8, 2024 – On June 25, 2024, Darby International Capital LLC ("Darby International") completed a successful exit of Pharma Consulting Group S.A. (“Biopas” or the “Company”) via a sale to Swixx Biopharma, a global medical commercial platform based in Switzerland.
With operational headquarters in Bogota, Colombia, Biopas is one of Latin America’s leading independent marketing and distribution companies for international biopharmaceutical firms. Biopas has a presence in 20 countries, including Latam’s “Top 5“ markets of Argentina, Brazil, Chile, Colombia and Mexico.
Darby International invested in Biopas in 2019 through Darby Latin American Private Debt Fund III.
“Our investment in Biopas was instrumental for the company to enter new markets, including Brazil and Mexico, as well as to expand its product offering during the last 5 years” said Ignacio Aicardi, Chief Investment Officer at Darby International. “The Company has grown to $220 million in sales with a presence in 20 countries in Latin America”.
About Darby International Capital LLC
Darby International is a leading emerging markets private debt investor with a focus on Latin America and has offices in Washington, DC, Bogotá, Colombia, and São Paulo, Brazil. The firm was created after the team spun off from its previous firm, Darby Overseas Investments, Ltd. (a subsidiary of Franklin Resources, Inc.).
Darby International is not affiliated with Darby Overseas Investments, Ltd., Darby Overseas Partners, L.P., Franklin Resources, Inc. (NYSE: BEN) or any of their affiliates.
For more information, visit www.darbyinternational.com or contact us at info@darbyinternational.com.